Abstract:Background: For programmed cell death protein 1/programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC), the addition of immune checkpoint inhibitors (ICIs) to chemotherapy has been shown to increase the objective response rate (ORR) by only 13.4-16.3%. Thus, examining converting tumor immunogenicity and targeting novel pathways may be needed to improve response to immunotherapy. B7-H4 is an emerging target for breast cancer immunotherapy. However, the antitumor effect of B7-H4 is unstable during cell generation and further research is necessary to strengthen the antitumor efficacy of B7-H4.Methods: To explore the potential of B7-H4-targeted immunotherapy of breast cancer, current study generated four monoclonal antibodies (mAbs) against B7-H4 through immunization of mice followed by phage display technology. T cell-engaged bispecific antibodies and immunotoxins were created based on these mAbs. To evaluate the anti-tumor activity of B7-H4-targeting bispecific antibody and immunotoxin, the anti-tumor efficacy test in vitro and in mice models in vivo were performed. Moreover, to boost the efficacy, oncolytic virus herpes simplex virus type 2 (HSV-2) was combined with the bispecific antibody and tested in mice models.Results: Rigorous in vitro cytotoxicity assay showed that both B7-H4 bispecific antibodies and immunotoxins were toxic to B7-H4 positive cells, with the former being more potent. However, in vivo studies showed that immunotoxin was slightly more effective in suppressing tumor growth. Further, bispecific antibody combined with oncolytic virus HSV-2 revealed a synergistic effect in suppressing tumor growth without causing obvious adverse effects.Conclusions: Collectively, our findings uncover a novel strategy of combining oncolytic virus HSV-2 with bispecific antibody reinforce antitumor immune response, which warranted further translational investigation.

Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells.

Functional Expression of B7H1 on Pancreatic Carcinoma Panc-1 Cells

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Expression of B7 Costimulator in Eight Human Malignant Hematological Cell Lines and Its Significance.

B7-H4 enhances oncogenicity and inhibits apoptosis in pancreatic cancer cells

Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

Co-stimulating molecule B7-H3 and tumors

Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells.

B7H Costimulates Clonal Expansion Of, and Cognate Destruction of Tumor Cells By, CD8+ T Lymphocytes in Vivo

Silencing B7-H1 Enhances the Anti-Tumor Effect of Bladder Cancer Antigen-Loaded Dendritic Cell Vaccine in Vitro

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Inoculation with IL-2 and B7-1 Co-Transfected G422 Murine Glioblastoma Cells Resulting in Enhanced Antitumor Immunity in Vivo

Triple Expression of B7-1, B7-2 and 4-1BBL Enhanced Antitumor Immune Response Against Mouse H22 Hepatocellular Carcinoma

Expression of B7-1 and B7-2 Mediated by Adenovirus Enhanced T Cell Anti-Hepatoma Immunity

B7-H3 in tumors: friend or foe for tumor immunity?

Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells

B7-H4’s Role “Beyond the Tumor”

Antitumor Effects Induced by B7-1 Gene Modified EL-4 Lymphoma Cooperated with IL-2in Vivo Andin Vitro

Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus

Study on Expression of Cytokines Mrna Induced by B7-1-transfected Raji and Jurkat Cells

B7-H6 is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma